Jefferies Group LLC reiterated their hold rating on shares of Radius Health, Inc. (NASDAQ:RDUS) in a research report released on Wednesday morning. The brokerage currently has a $38.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $34.00.
A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald reiterated a buy rating and set a $65.00 price objective on shares of Radius Health in a report on Friday, April 28th. Zacks Investment Research upgraded shares of Radius Health from a sell rating to a hold rating in a report on Thursday, May 4th. Canaccord Genuity reiterated a buy rating on shares of Radius Health in a report on Friday, April 28th. HC Wainwright reiterated a buy rating and set a $63.00 price objective on shares of Radius Health in a report on Monday, May 15th. Finally, Maxim Group reiterated a sell rating on shares of Radius Health in a report on Monday, May 1st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. Radius Health presently has a consensus rating of Hold and a consensus target price of $53.60.
Radius Health (NASDAQ:RDUS) traded up 4.01% during trading on Wednesday, reaching $35.54. 1,995,313 shares of the company were exchanged. Radius Health has a 1-year low of $31.58 and a 1-year high of $59.88. The company’s 50-day moving average price is $43.44 and its 200-day moving average price is $40.37. The stock’s market capitalization is $1.55 billion.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by $0.23. The company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same period last year, the firm earned ($1.01) EPS. On average, equities analysts forecast that Radius Health will post ($5.51) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Radius Health’s (NASDAQ:RDUS) Hold Rating Reiterated at Jefferies Group LLC” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://stocknewstimes.com/2017/08/12/radius-healths-nasdaqrdus-hold-rating-reiterated-at-jefferies-group-llc.html.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 50,000 shares of Radius Health stock in a transaction dated Thursday, May 18th. The stock was acquired at an average price of $34.41 per share, for a total transaction of $1,720,500.00. Following the acquisition, the insider now owns 4,958,799 shares in the company, valued at approximately $170,632,273.59. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech purchased 35,000 shares of Radius Health stock in a transaction dated Wednesday, May 17th. The stock was acquired at an average price of $33.44 per share, with a total value of $1,170,400.00. Following the acquisition, the insider now owns 4,890,799 shares in the company, valued at approximately $163,548,318.56. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 315,000 shares of company stock valued at $10,954,800. Company insiders own 15.00% of the company’s stock.
Large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after buying an additional 2,628,070 shares in the last quarter. TimesSquare Capital Management LLC acquired a new stake in Radius Health during the second quarter valued at approximately $25,589,000. BB Biotech AG raised its stake in Radius Health by 11.0% in the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after buying an additional 498,400 shares in the last quarter. Norges Bank acquired a new stake in Radius Health during the fourth quarter valued at approximately $13,519,000. Finally, Credit Agricole S A acquired a new stake in Radius Health during the first quarter valued at approximately $10,026,000.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.